Pharvaris (NASDAQ:PHVS – Get Rating) – Equities researchers at SVB Leerink cut their Q3 2022 earnings per share (EPS) estimates for Pharvaris in a report issued on Tuesday, September 13th. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings of ($0.65) per share for the quarter, down from their prior forecast of ($0.60). SVB Leerink currently has a "Outperform" rating and a $20.00 target price on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.18) per share. SVB Leerink also issued estimates for Pharvaris' Q4 2022 earnings at ($0.65) EPS, FY2022 earnings at ($2.18) EPS, Q1 2023 earnings at ($0.67) EPS, Q2 2023 earnings at ($0.68) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.57) EPS, FY2023 earnings at ($2.23) EPS and FY2024 earnings at ($1.90) EPS.
Get Pharvaris alerts:Several other research firms have also recently issued reports on PHVS. Bank of America cut Pharvaris from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $26.00 to $13.00 in a research report on Monday, August 22nd. JMP Securities reduced their price objective on Pharvaris from $34.00 to $18.00 and set a "mkt outperform" rating for the company in a research note on Tuesday. Morgan Stanley downgraded Pharvaris from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $40.00 to $10.00 in a research note on Tuesday, August 23rd. Finally, Oppenheimer reduced their price objective on Pharvaris from $48.00 to $22.00 and set an "outperform" rating for the company in a research note on Tuesday, August 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $16.60.
Pharvaris Trading Down 1.8 %
Shares of NASDAQ PHVS opened at $9.12 on Friday. Pharvaris has a twelve month low of $8.55 and a twelve month high of $27.50. The stock has a market capitalization of $290.38 million, a PE ratio of -4.88 and a beta of -0.19. The stock has a fifty day simple moving average of $16.13 and a 200-day simple moving average of $17.87.Pharvaris (NASDAQ:PHVS – Get Rating) last announced its quarterly earnings data on Monday, September 12th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.19.
Hedge Funds Weigh In On Pharvaris
A number of large investors have recently modified their holdings of PHVS. Goldman Sachs Group Inc. grew its holdings in shares of Pharvaris by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock worth $1,259,000 after acquiring an additional 1,115 shares during the period. Bank of America Corp DE grew its holdings in shares of Pharvaris by 1,054.4% in the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock worth $105,000 after acquiring an additional 5,272 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company's stock worth $5,659,000 after acquiring an additional 57,694 shares during the period. Viking Global Investors LP grew its holdings in shares of Pharvaris by 1.0% in the 1st quarter. Viking Global Investors LP now owns 2,480,319 shares of the company's stock worth $46,382,000 after acquiring an additional 24,783 shares during the period. Finally, Suvretta Capital Management LLC acquired a new stake in shares of Pharvaris in the 4th quarter worth approximately $11,908,000. 70.21% of the stock is owned by hedge funds and other institutional investors.
Pharvaris Company Profile
(Get Rating)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Read More
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.